PDC*line Pharma
PDC*line Pharma is a Belgian-French clinical-stage biotech developing off-the-shelf, antigen-specific cancer immunotherapies based on an engineered plasmacytoid dendritic cell line platform, with its lead candidate PDC*lung01 in Phase I/II for NSCLC.
- Company typePrivate
- Founded2014
- HeadquartersLa Tronche, France
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What PDC*line Pharma does
PDC*line Pharma is a Belgian-French clinical-stage biotechnology company founded in April 2014 as a spin-off of the Établissement Français du Sang (EFS), the French National Blood Service. The company is developing a new class of off-the-shelf (allogeneic) antigen-specific cancer immunotherapies based on its proprietary PDC*line platform — an engineered Plasmacytoid Dendritic Cell (PDC) line pre-loaded with tumor-associated antigen peptides that prime T cells to recognize and attack cancer cells. Its lead clinical candidate, PDC*lung01, is in Phase I/II development for non-small cell lung cancer (NSCLC), with Phase I/II data presented at ESMO, ELCC, and AACR through 2025 demonstrating safety and expansion of tumor-specific CD8+ cytotoxic T cells when combined with anti-PD-1 therapy. A second program, PDC*Neo, extends the platform to personalized neoantigen targeting. Earlier validation came from the GeniusVac-Mel4 Phase Ib study in melanoma, which established clinical proof-of-concept through demonstrated safety and antigen-specific T-cell priming.
The company operates from two strategic hubs: its operational headquarters in Liège, Belgium, and its R&D center in Grenoble, France, supported by a multidisciplinary team of 1-10 immunology, oncology, biotech engineering, and clinical research professionals. As a privately held company, PDC*line Pharma has raised approximately $46M+ across three funding rounds in 2016, 2020, and 2021, with investors including SFPI-FPIM, S.R.I.W., Sambrinvest, Noshaq, Korea Investment Partners, Alpha Holdings, Hansongneotech, UTC Investment Co., and Shinhan-Cognitive Start-up Fund. Its go-to-market motion is enterprise-field-sales oriented, preparing for eventual commercialization through oncology-focused channels targeting hospitals, cancer treatment centers, and thoracic oncology specialists, while currently distributing its investigational products through multi-center Phase I/II clinical trial sites across Belgium, the Netherlands, France, Germany, and other European countries.
PDC*line Pharma firmographics
Firmographics- Name
- PDC*line Pharma
- Legal name
- PDC*line Pharma
- Website
- https://pdc-line-pharma.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PDC*line Pharma is a Belgian-French clinical-stage biotech developing off-the-shelf, antigen-specific cancer immunotherapies based on an engineered plasmacytoid dendritic cell line platform, with its lead candidate PDC*lung01 in Phase I/II for NSCLC.
- Ownership category
- akta.pro rank
PDC*line Pharma industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Dendritic Cell & Other APC-based Therapies (HLAAABAF)
- akta.pro secondary industries
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)
Keywords
Where PDC*line Pharma is headquartered
LocationHeadquarters
- HQ city
- La Tronche
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
PDC*line Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Development: As a clinical-stage biopharmaceutical company, PDC*line Pharma is developing investigational cancer immunotherapies that have not yet received regulatory approval. The company is currently in the clinical development phase with PDC*lung01 for NSCLC and PDC*Neo for neoantigen-based therapy. Revenue generation will depend on successful clinical development, regulatory approval, and eventual commercialization of therapeutic products.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
PDC*line Pharma product offering
Product offeringCore offering
PDC*line Pharma develops off-the-shelf (allogeneic) antigen-specific cancer immunotherapies based on a proprietary engineered Plasmacytoid Dendritic Cell (PDC) line pre-loaded with tumor-associated antigen peptides. The company's lead clinical candidate, PDC*lung01, targets non-small cell lung cancer and is currently in Phase I/II development, with PDC*Neo (neoantigen program) and GeniusVac-Mel4 (melanoma) also in the pipeline.
Product overview
PDC*line Pharma is a Belgian-French biotechnology company developing a new class of off-the-shelf (allogeneic) antigen-specific cancer immunotherapies. The proprietary PDC*line platform serves as the core technology foundation, enabling reproducible, scalable manufacturing of Plasmacytoid Dendritic Cell-based cancer vaccines. The company's clinical pipeline centers on PDC*lung01 (lead candidate for non-small cell lung cancer), while PDC*Neo advances a next-generation neoantigen targeting approach. The platform was initially validated through the GeniusVac-Mel4 Phase I trial in melanoma.
Differentiator
Problem solved
Functional benefit
Products and services
- PDC*line Platform Proprietary patented technology platform based on an engineered Plasmacytoid Dendritic Cell (PDC) line pre-loaded with tumor antigens, enabling off-the-shelf (allogeneic) antigen-specific cancer immunotherapy. Standardizes rare immune cells into a reproducible, scalable cell line that can prime T cells to recognize and attack cancer cells.
- PDC*lung01 Lead clinical candidate: a PDC*line-based therapeutic cancer vaccine pre-loaded with peptides targeting tumor antigens expressed in non-small cell lung cancer (NSCLC), currently in Phase I/II clinical development.
- PDC*Neo Next-generation neoantigen program combining the scalable PDC*line off-the-shelf platform with personalized neoantigen targeting for precision oncology.
- GeniusVac-Mel4 First-in-human Phase I clinical trial of a PDC*line-based cancer vaccine in melanoma patients, demonstrating successful priming and expansion of antitumor T-cells and establishing clinical proof-of-concept for the PDC*line platform.
Quantifiable outcome
- Phase I melanoma trial demonstrated safety, tolerability, and induction of meaningful antigen-specific T-cell responses
- +3 more outcomes
Companies that use PDC*line Pharma
Customer profileSegments3 records
Ideal customer profiles2 records
PDC*line Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
PDC*line Pharma partnerships and signals
Strategic signalScale indicators1 record
Recent moves7 records
Expansion highlights5 records
PDC*line Pharma competitors and assessment
Company assessmentBroad incumbents
- Iovance Biotherapeutics: Iovance is a leading commercial-stage TIL (tumor-infiltrating lymphocyte) cell therapy company. Relevant as a benchmark for cell therapy commercialization in solid tumors.
- Cellectis: Cellectis is a French clinical-stage biotech pioneering allogeneic CAR-T cell therapies with broader gene-editing capabilities. Comparable as a European cell therapy platform company with allogeneic manufacturing focus.
- Adaptimmune Therapeutics: Adaptimmune develops SPEAR T-cell receptor (TCR) therapies for solid tumors. Comparable as a clinical-stage cell therapy company targeting solid tumor antigens with engineered T-cell approaches.
- BioNTech: BioNTech is a major mRNA-based immunotherapy company with a leading personalized neoantigen cancer vaccine program (BNT122). Direct comparator to PDC*Neo for neoantigen-targeted immunotherapy in solid tumors.
- Moderna: Moderna is developing mRNA-based personalized cancer vaccines (mRNA-4157) and oncology immunotherapies. Relevant emerging competitor in the personalized neoantigen cancer vaccine space.
Direct peers
- Sotio Biotech: Sotio is a Czech clinical-stage biotech developing dendritic cell-based immunotherapies (e.g., DCVAC products) for cancer. It is the closest direct peer to PDC*line given shared focus on dendritic cell vaccines for solid tumors.
- Immunicum AB: Immunicum is a Swedish biotech developing allogeneic off-the-shelf cell-based cancer immunotherapies using a different cell platform (dendritic cells loaded with tumor material). Direct comparator for allogeneic cell therapy approach in oncology.
- Northwest Biotherapeutics: Northwest Biotherapeutics develops DCVax, an autologous dendritic cell-based immunotherapy for glioblastoma and other solid tumors. Closely comparable dendritic cell vaccine modality.
- Transgene: Transgene is a French clinical-stage biotech developing viral vector-based immunotherapies (including TG4050, a personalized neoantigen vaccine). Comparable as a European biotech targeting solid tumor neoantigens with active immunization approaches.
Emerging players
- Medigene: Medigene is a German clinical-stage biotech developing TCR-based immunotherapies for solid tumors. Comparable as a European cell-based immunotherapy developer focused on antigen-specific T-cell responses.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
PDC*line Pharma social profiles
Digital presencePDC*line Pharma compliance and trust
Trust signalCompliance1 record
PDC*line Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
PDC*line Pharma leadership team
Management profileNumber of profiles
Profiles1 record
PDC*line Pharma funding detail
Funding detailFunding overview
Funding rounds5 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PDC*line Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PDC*line Pharma
What does PDC*line Pharma do?
PDC*line Pharma develops off-the-shelf (allogeneic) antigen-specific cancer immunotherapies based on a proprietary engineered Plasmacytoid Dendritic Cell (PDC) line pre-loaded with tumor-associated antigen peptides. The company's lead clinical candidate, PDC*lung01, targets non-small cell lung cancer and is currently in Phase I/II development, with PDC*Neo (neoantigen program) and GeniusVac-Mel4 (melanoma) also in the pipeline.
Is PDC*line Pharma a public or private company?
PDC*line Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was PDC*line Pharma founded?
PDC*line Pharma was founded in 2014. It employs 1 to 10 people.
Where is PDC*line Pharma based?
PDC*line Pharma is headquartered in La Tronche, France, in the Europe region.
How does PDC*line Pharma make money?
One revenue line is on record: pharmaceutical Development.
Who are PDC*line Pharma's main competitors?
Broad incumbents on record are Iovance Biotherapeutics, Cellectis, Adaptimmune Therapeutics, BioNTech and Moderna. Direct peers are Sotio Biotech, Immunicum AB, Northwest Biotherapeutics and Transgene. Medigene is listed as an emerging player.
Does PDC*line Pharma have an API?
No public API is recorded for PDC*line Pharma.
What industry is PDC*line Pharma in?
PDC*line Pharma's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAF, Dendritic Cell & Other APC-based Therapies, with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.